Dapagliflozin · Farxiga / Forxiga
Small molecule
Evidence outlook
Approved: Type 2 Diabetes, Heart Failure, Chronic Kidney Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Atherosclerotic Cardiovascular Disease · Phase 3 · investigational in the US
Also approved (2)
- Type 2 diabetes mellitus (Forxiga 5 mg, 10 mg tablets)
- Type 2 diabetes (Forxiga; later extended to chronic heart failure and chronic kidney disease)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00528372 NCT00528372 · Type 2 Diabetes The study was randomized, double-blind, placebo-controlled, and included 1,067 enrolled participants, with 558 receiving short-term treatment; its primary HbA1c endpoint is an accepted disease-defining measure for type 2 diabetes. Results were mixed across the primary dose comparisons: 5 mg and 10 mg morning doses significantly outperformed placebo, while 2.5 mg did not, and the exploratory high-baseline-HbA1c group lacked a comparator. Registry: NCT00528372 | 3 | Adjusted Mean Change From Baseline to Week 24 in Hemoglobin A1C (HbA1c) (Last Observation Carried Forward [LOCF]): Group 1 (Baseline to Week 24 (end of Short-term Period)); Adjusted Mean Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c) (Last Observation Carried Forward [LOCF]): Group 2 (Baseline to Week 24 (end of Short-term Period)) 2009-02 | Adjusted Mean Change From Baseline to Week 24 in Hemoglobin A1C (HbA1c) (Last Observation Carried Forward [LOCF]): Group 1 (Baseline to Week 24 (end of Short-term Period)): Group 1: Dapagliflozin, 2.5 mg AM -0.58 Percent (Standard Error 0.1107) | Group 1: Dapagliflozin, 5 mg AM -0.77 Percent (Standard Error 0.1134) | Group 1: Dapagliflozin, 10 mg AM -0.89 Percent (Standard Error 0.1099) | Group 1: Dapagliflozin, 2.5 mg PM -0.83 Percent (Standard Error 0.1125) | Group 1: Dapagliflozin, 5 mg PM -0.79 Percent (Standard Error 0.1117) | Group 1: Dapagliflozin, 10 mg PM -0.79 Percent (Standard Error 0.1037) vs Group 1: Dapagliflozin Placebo AM & PM -0.23 Percent (Standard Error 0.1044) | Partial signal | link ↗ |
View 14 more trials
NCT00357370 NCT00357370 · Type 2 Diabetes The study was randomized, double-blind, and placebo-controlled, but only 71 participants were randomized, making it a small pilot trial. Its primary endpoint was the surrogate measure HbA1c, and although adjusted changes favored dapagliflozin, the registry reports no formal statistical test, so the primary result is unclear. Registry: NCT00357370 | 2/3 | Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 12 (Last Observation Carried Forward [LOCF]) - Cohort 2 (From Baseline to Week 12) 2008-03 | Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 12 (Last Observation Carried Forward [LOCF]) - Cohort 2 (From Baseline to Week 12): Dapagliflozin 10 mg -0.61 % of hemoglobin (Standard Error 0.1276) | Dapagliflozin 20 mg -0.69 % of hemoglobin (Standard Error 0.1278) vs Placebo 0.09 % of hemoglobin (Standard Error 0.1406) | Partial signal | link ↗ |
NCT00859898 NCT00859898 · Type 2 Diabetes This was a randomized, quadruple-blind trial with an active metformin comparator, and every primary HbA1c comparison succeeded: the combination beat both single drugs, and dapagliflozin alone was shown to be no worse than metformin. No sample-size calculation or planned enrolment is reported in the sources checked, so adequate power cannot be confirmed. Registry: NCT00859898 | 3 | Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 (Last Observation Carried Forward) - Randomized Treated Participants 2010-05 | Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 (Last Observation Carried Forward) - Randomized Treated Participants (Week 24): Dapagliflozin + Metformin XR -1.98 Percent of hemoglobin (Standard Error 0.0759) | Dapagliflozin -1.45 Percent of hemoglobin (Standard Error 0.0734) vs Metformin XR -1.44 Percent of hemoglobin (Standard Error 0.0757) | Partial signal | link ↗ |
NCT00643851 NCT00643851 · Type 2 Diabetes The study was randomized, double-blind, and active-controlled, with 603 randomized participants and a clinically relevant HbA1c primary endpoint that met its prespecified superiority comparison against both dapagliflozin alone and metformin XR (p<0.0001 for each). However, the available record does not report a power or sample-size calculation, so the evidence is rated moderate rather than strong. Registry: NCT00643851 | 3 | Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]) (From Baseline to Week 24) 2009-08 | Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]) (From Baseline to Week 24): Dapagliflozin 5 mg + Metformin XR -2.05 % of hemoglobin (Standard Error 0.0892) | Dapagliflozin 5 mg -1.19 % of hemoglobin (Standard Error 0.0866) vs Metformin XR -1.35 % of hemoglobin (Standard Error 0.0868) | Partial signal | link ↗ |
NCT00528879 NCT00528879 · Type 2 Diabetes The trial randomized 546 participants to three dapagliflozin doses or matching placebo, with participants and investigators blinded; metformin was continued openly in all groups. Its primary HbA1c endpoint, an accepted clinical measure for type 2 diabetes, was statistically significantly better for every dapagliflozin dose, but the record does not report the power calculation needed to verify that the study was adequately powered. Registry: NCT00528879 | 3 | Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]) (From Baseline to Week 24) 2008-11 | Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]) (From Baseline to Week 24): Dapagliflozin, 2.5 mg + Metformin -0.67 Percent (Standard Error 0.0715) | Dapagliflozin, 5 mg + Metformin -0.7 Percent (Standard Error 0.0722) | Dapagliflozin, 10 mg + Metformin -0.84 Percent (Standard Error 0.0724) vs Placebo + Metformin -0.3 Percent (Standard Error 0.0718) | Partial signal | link ↗ |
NCT00660907 NCT00660907 · Type 2 Diabetes The trial was randomized, quadruple-blind, and actively controlled, with 814 randomized participants and a clinical primary endpoint based on HbA1c. The prespecified non-inferiority comparison was met (p<0.0001), but the record does not report a power calculation and 814 participants were randomized versus a planned 816, so the evidence is graded moderate rather than strong. Registry: NCT00660907 | 3 | Adjusted Mean Change in HbA1c Levels (Baseline to Week 52) 2009-12 | Adjusted Mean Change in HbA1c Levels (Baseline to Week 52): Dapagliflozin Plus Metformin -0.52 percent (95% CI -0.6 to -0.44) vs Glipizide Plus Metformin -0.52 percent (95% CI -0.6 to -0.44) | Partial signal | link ↗ |
NCT00680745 NCT00680745 · Type 2 Diabetes The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 597 participants, using HbA1c change as its primary clinical endpoint; all three dapagliflozin comparisons significantly favored treatment. A moderate grade is suggested because no primary-endpoint power or sample-size calculation is reported in the provided sources, so adequate powering cannot be confirmed. Registry: NCT00680745 | 3 | Adjusted Mean Change in HbA1c Levels (Baseline to Week 24) 2009-11 | Adjusted Mean Change in HbA1c Levels (Baseline to Week 24): Dapagliflozin 2.5mg + Glimepiride -0.58 Percent (95% CI -0.69 to -0.46) | Dapagliflozin 5mg + Glimepiride -0.63 Percent (95% CI -0.75 to -0.5) | Dapagliflozin 10mg + Glimepiride -0.82 Percent (95% CI -0.94 to -0.7) vs Placebo + Glimepiride -0.13 Percent (95% CI -0.26 to -0.01) | Partial signal | link ↗ |
NCT01392677 NCT01392677 · Type 2 Diabetes The trial was randomized, quadruple-blind, and placebo-controlled, with 219 participants randomized and an objective HbA1c primary endpoint that was significantly better with dapagliflozin. It is graded moderate because the supplied record does not report the power calculation or planned enrollment needed to verify that the study was adequately powered. Registry: NCT01392677 | 3 | Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24) 2013-01 | Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02) | Partial signal | link ↗ |
NCT00683878 NCT00683878 · Type 2 Diabetes The trial randomized 420 treated participants to dapagliflozin 5 mg, dapagliflozin 10 mg, or matching placebo, with participants and investigators blinded; its primary HbA1c endpoint was met for both dapagliflozin doses. The evidence is graded moderate because no power calculation is reported in the available record, despite the objective, regulator-accepted HbA1c endpoint and statistically significant results. Registry: NCT00683878 | 3 | Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]) (From Baseline to Week 24) 2010-01 | Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]) (From Baseline to Week 24): Dapagliflozin 5MG + Pioglitazone -0.82 % of hemoglobin (Standard Error 0.0828) | Dapagliflozin 10MG + Pioglitazone -0.97 % of hemoglobin (Standard Error 0.0828) vs PLACEBO + Pioglitazone -0.42 % of hemoglobin (Standard Error 0.0834) | Partial signal | link ↗ |
NCT00984867 NCT00984867 · Type 2 Diabetes The study was randomized, quadruple-blind, and placebo-controlled, with 452 participants randomized and a clinical HbA1c primary endpoint that was met in favor of dapagliflozin. It is graded moderate because the available record does not report a power calculation showing that the enrolled sample met the prespecified requirement. Registry: NCT00984867 | 3 | Adjusted Mean Change in HbA1c Levels (Baseline to Week 24) 2011-03 | Adjusted Mean Change in HbA1c Levels (Baseline to Week 24): Dapagliflozin -0.45 Percent (95% CI -0.55 to -0.35) vs Placebo 0.04 Percent (95% CI -0.06 to 0.14) | Partial signal | link ↗ |
NCT00673231 NCT00673231 · Type 2 Diabetes The trial was randomized, quadruple-blind, and placebo-controlled, with 1,240 participants enrolled and 807 randomized across the four arms; its primary HbA1c endpoint was statistically significantly better with each dapagliflozin dose than with placebo. The registry does not provide a power calculation, so the available record supports a moderate rather than the highest evidence grade despite the otherwise strong design. Registry: NCT00673231 | 3 | Adjusted Mean Change in HbA1c Levels (Baseline to Week 24) 2009-05 | Adjusted Mean Change in HbA1c Levels (Baseline to Week 24): Dapagliflozin 2.5mg -0.75 Percent (95% CI -0.85 to -0.65) | Dapagliflozin 5mg -0.82 Percent (95% CI -0.92 to -0.73) | Dapagliflozin 10mg -0.9 Percent (95% CI -1 to -0.8) vs Placebo -0.3 Percent (95% CI -0.4 to -0.2) | Partial signal | link ↗ |
DERIVE NCT02413398 · Type 2 Diabetes Patients were randomly assigned to dapagliflozin or a matching placebo, with patients and investigators blinded, and HbA1c, the standard measure of blood sugar control in diabetes, fell significantly more with dapagliflozin (difference -0.34 percentage points, p<0.001). The study reported a sample-size calculation requiring 302 randomized patients and enrolled 321. Registry: NCT02413398 | 3 | Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 (Baseline, Week 24) 2017-11-07 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
NCT03199053 NCT03199053 · Type 2 Diabetes Participants were randomly assigned to dapagliflozin, saxagliptin or a matching placebo, with participants and investigators blinded, and HbA1c fell significantly more with dapagliflozin than with placebo at week 26 (difference -1.03 percentage points, p<0.001). The protocol's sample-size calculation required 243 randomized and analysed participants, and 245 were randomized and analysed. Registry: NCT03199053 | 3 | Dapagliflozin Versus Placebo: Adjusted Mean Change From Baseline in HbA1c at Week 26 (Baseline and Week 26); Saxagliptin Versus Placebo: Adjusted Mean Change From Baseline in HbA1c at Week 26 (Baseline and Week 26) 2023-02-01 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
DECLARE-TIMI58 NCT01730534 · Type 2 Diabetes This was a large randomized, quadruple-blind, placebo-controlled outcomes trial with two co-primary endpoints. One was met (cardiovascular death or heart failure hospitalization, hazard ratio 0.83, p=0.005) and the other was not (cardiovascular death, heart attack or ischemic stroke, hazard ratio 0.93, p=0.172), so the primary result is mixed. Registry: NCT01730534 | 3 | Subjects Included in the Composite Endpoint of CV Death, MI or Ischemic Stroke (up to 5.2 years); Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure. (up to 5.2 years) 2018-09-11 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT02229396 NCT02229396 · Diabetes Mellitus The study randomized 695 participants and used double blinding with active treatment comparisons; its primary endpoint was the clinically accepted diabetes measure HbA1c. The primary endpoint was met, with the combination significantly outperforming dapagliflozin alone and exenatide alone, but the available record does not report the sample-size power calculation needed to confirm that the study was adequately powered. Registry: NCT02229396 | 3 | Change in HbA1c From Baseline to Week 28 2016-04-26 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (122)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (26)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (85)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (81)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (177)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (48)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (27)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Phase 4 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Studied as part of a combination product (1)
Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.
Phase 1 (1)
What this study did
Appears in other studies (9)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other SGLT2 drugs
Bexagliflozin, Canagliflozin, Empagliflozin, Ertugliflozin, Enavogliflozin and 5 more. Compare all 11 SGLT2 drugs
This mechanism is crowded: 10 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Atherosclerotic Cardiovascular Disease: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Dapagliflozin (Farxiga / Forxiga): this drug | Phase 3 | Small molecule | SGLT2 | not yet graded | No reviewed efficacy summary in this indication | |
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | Weak signal | NCT03510884: DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Alirocumab Q2W -33.6 percent change (Standard Error 3.4) | Db Period: Alirocumab Q4W -38.2 percent change (Standard Error 4) vs DB Period: Placebo Q2W 9.7 percent change (Standard Error 4.3) | Db Period: Placebo Q4W -4.4 percent change (Standard Error 3.7) NCT01709500: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis (From Baseline to Week 52): Alirocumab 75 mg/up to 150 mg -48.7 percent change (Standard Error 1.9) vs Placebo 2.8 percent change (Standard Error 2.8) | |
| Bempedoic Acid (Nexletol) | Approved | Small molecule | ATP citrate lyase | Partial signal | NCT02991118: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid -15.07 percent change (Standard Error 1.073) vs Placebo 2.35 percent change (Standard Error 1.446) NCT02988115: Percent Change From Baseline (PCFB) in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline; Week 12): Bempedoic Acid -22.58% (Standard Error 1.29) vs Placebo -1.17% (Standard Error 1.421) | |
| Bempedoic Acid / Ezetimibe (Nexlizet) | Approved | Small molecule | ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe) | Partial signal | NCT03337308: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC -36.2% (Standard Error 2.56) vs Bempedoic Acid 180 mg -17.2% (Standard Error 2.52) vs Ezetimibe 10 mg -23.2% (Standard Error 2.18) vs Placebo 1.8% (Standard Error 3.49) | |
| Cangrelor (Kengreal) | Approved | Small molecule | P2Y12 receptor | Partial signal | NCT00385138: Death, MI or ischemia-driven revascularization at 48 h: 7.0% cangrelor (185/2654) vs 8.0% placebo (210/2641); OR 0.87, 95% CI 0.71 to 1.07; P=0.17. Both arms received clopidogrel 600 mg (CHAMPION PLATFORM, NEJM 2009). missed | |
| Colchicine (cardiovascular) (Lodoco) | Approved | Small molecule | Microtubule/inflammasome (tubulin) | not yet graded | No reviewed efficacy summary in this indication | |
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | Reliable signal | NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952 | |
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | not yet graded | No reviewed efficacy summary in this indication | |
| Evolocumab (Repatha) | Approved | Monoclonal antibody | PCSK9 | Partial signal | NCT02392559: Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): EvoMab 420 mg QM -44.53 percent change (Standard Error 2.17) vs Placebo -6.23 percent change (Standard Error 3.08) NCT02207634: Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score (Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).): Evolocumab 0.1134 Z score (95% CI 0.0449 to 0.182) vs Placebo 0.1206 Z score (95% CI 0.0535 to 0.1877) | |
| Ezetimibe / Simvastatin (Vytorin) | Approved | Small molecule | HMG-CoA reductase / NPC1L1 | Reliable signal | NCT00202878: Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event) (Up to approximately 9 years): Ezetimibe/Simvastatin 32.72% (95% CI 31.63 to 33.85) vs Simvastatin 34.67% (95% CI 33.56 to 35.81) NCT00110435: Percent reduction in LDL-C from baseline at 6 weeks: ezetimibe/simvastatin 10/20mg -53.6% vs atorvastatin 10mg -38.3% (P<.001) and vs atorvastatin 20mg -44.6% (P<.001); ezetimibe/simvastatin 10/40mg -57.6% vs atorvastatin 40mg -50.9% (P<.001). Primary endpoint (percent change from baseline in LDL-C) significantly favored ezetimibe/simvastatin at both dose comparisons. | |
| Icosapent Ethyl (Vascepa) | Approved | Small molecule | Omega-3 fatty acid (EPA) | Reliable signal | NCT01492361: Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization. (Total follow-up time of up to approximately 6 years.): AMR101 705/4089 vs Placebo 901/4090 | |
| Liraglutide (Victoza) | Approved | Peptide | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Rosuvastatin | Approved | Small molecule | HMG-CoA reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Semaglutide (Ozempic) | Approved | Peptide | GLP-1 receptor | Reliable signal | NCT04560998: Maximum walking distance at Week 52: semaglutide 1 mg superior to placebo by 13% (estimated treatment ratio 1.13; 95% CI 1.06-1.21; p=0.0004); median treatment difference 26.4 meters (~87 feet) on a 12% incline treadmill NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9% | |
| Semaglutide (Rybelsus) | Approved | Peptide | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Semaglutide (Wegovy) | Approved | Peptide | GLP-1 receptor | Reliable signal | NCT03574597: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801 | |
| Ticagrelor (Brilinta) | Approved | Small molecule | P2Y12 receptor | Partial signal | Featured results are non-efficacy only in this race | |
| Tirzepatide (Mounjaro) | Approved | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| AG2304 | Phase 3 | Small molecule | HMG-CoA reductase / NPC1L1 | Partial signal | No reviewed efficacy summary in this indication | |
| Alprostadil | Phase 3 | Small molecule | Prostaglandin E1 receptor | not yet graded | NCT01263925: ClinicalTrials.gov results section for NCT01263925 ('Intravenous Prostaglandin E1 Treatment in Outpatients With Intermittent Claudication', UCB Pharma, Phase 3, enrollment 561/541 FAS, completed April 2011 -- matches this record exactly). Primary outcome: pain-free walking-distance ratio vs active comparator (pentoxifylline) across three periods; both treatments produced similar improvements with no clear superiority of either. phase 3 result · pivotal pending | |
| Amlodipine / Valsartan / Atorvastatin (CJ-30061) | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / HMG-CoA reductase | Partial signal | No reviewed efficacy summary in this indication | |
| Beperminogene Perplasmid (HGF Plasmid) (Collategene) | Phase 3 | Gene therapy / editing | HGF (hepatocyte growth factor), Hepatocyte growth factor (HGF) | not yet graded | No reviewed efficacy summary in this indication | |
| Cilostazol / Rosuvastatin (UI022 / UI023) | Phase 3 | Small molecule | PDE3 (phosphodiesterase 3) and HMG-CoA reductase | Reliable signal | NCT07600385: KPAQ summary score change (FAS, n=257): test group 15.41 points (SD 14.18) vs control group 10.27 points (SD 14.70); between-group difference 5.14 points (P=0.004), test group superior. | |
| Dalcetrapib | Phase 3 | Small molecule | CETP | Partial signal | NCT00658515: Primary composite cardiovascular endpoint, dalcetrapib vs placebo: hazard ratio 1.04 (95% CI 0.93 to 1.16), P=0.52; trial stopped for futility (NEJM 2012). missed NCT01059682: Nominal Change From Baseline to Study End in Coronary Percent Atheroma Volume (PAV) of the Target Coronary Artery Assessed by IVUS. (24 months): Dalcetrapib 0.6% (Standard Deviation 3.69) vs Placebo 0.5% (Standard Deviation 2.01) | |
| DWC202206 + DWC202207 | Phase 3 | Small molecule | — | Partial signal | No reviewed efficacy summary in this indication | |
| Ebronucimab | Phase 3 | Monoclonal antibody | PCSK9 | Partial signal | NCT05255094: LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001). | |
| Enlicitide (Lipfendra) | Phase 3 | Peptide | PCSK9 | Reliable signal | NCT05952856: Week 24 LDL-C mean percent change: -57.1% with enlicitide vs 3.0% with placebo; difference -55.8 percentage points (95% CI -60.9 to -50.7; p<0.001). NCT05952869: Mean Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (Baseline and Week 24): Enlicitide Decanoate -58.2% (Standard Deviation 28) vs Placebo 2.6% (Standard Deviation 23.6) | |
| Ezetimibe (Zetia) | Phase 3 | Small molecule | Dietary Cholesterol Absorption Inhibitor, NPC1L1 | Reliable signal | NCT00092586: Percent change in LDL-C: ezetimibe+statin -25.8% vs placebo+statin -2.7%; treatment difference -23.1 percentage points (P<.001) NCT03867318: Proportion achieving LDL-C goal <=100 mg/dL at Week 14: 22% (ezetimibe 10mg + atorvastatin, n=305) vs 7% (atorvastatin dose-titration alone, n=316); P<.01 | |
| Fimasartan / Atorvastatin / Ezetimibe (BR1017) | Phase 3 | Small molecule | AT1 receptor; NPC1L1; HMG-CoA reductase | Partial signal | NCT05930028: Week 8 co-primary endpoints (full analysis set, 148 randomized): mean sitting systolic BP, fimasartan + atorvastatin/ezetimibe vs atorvastatin/ezetimibe, LS mean difference -7.26 mm Hg (95% CI -12.91 to -1.61), P = 0.0124; LDL-C percent change, fimasartan + atorvastatin/ezetimibe vs fimasartan, LS mean difference -58.02% (95% CI -66.03 to -50.02), P < 0.0001 (Hong et al., Clin Ther 2025). | |
| Hyzetimibe | Phase 3 | Small molecule | NPC1L1 | Partial signal | NCT03433196: LDL-C percent change from baseline (primary endpoint, week 12): -16.39% (95% CI -19.04 to -13.74) with hyzetimibe (HS-25, referred to in this paper as hybutimibe) + atorvastatin vs -6.75% (95% CI -9.48 to -4.02) with atorvastatin alone, P<0.0001 NCT03413462: 第12周试验组LDL-C较基线的变化率为(-10.23±13.58)%,显著优于对照组(4.34±15.88)%。 | |
| Inclisiran (Leqvio) | Phase 3 | RNA / oligonucleotide | PCSK9 | Partial signal | NCT04652726: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -27.14% (95% CI -32.04 to -22.24) vs Part 1 - Placebo 1.4% (95% CI -3.97 to 6.78) NCT04659863: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52) | |
| Laroprovstat | Phase 3 | Small molecule | PCSK9 | Reliable signal | NCT06173570: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): AZD0780 1 mg -31.19% (95% CI -37.06--25.32) vs AZD0780 3 mg -33.83% (95% CI -39.78--27.88) vs AZD0780 10 mg -41.09% (95% CI -46.92--35.25) vs AZD0780 30 mg -46.62% (95% CI -52.48--40.76) vs Placebo 4.08% (95% CI -1.84-10.00); p=< 0.001 (AZD0780 1 mg vs Placebo), p=< 0.001 (AZD0780 3 mg vs Placebo), p=< 0.001 (AZD0780 10 mg vs Placebo), p=< 0.001 (AZD0780 30 mg vs Placebo) | |
| Laroprovstat / Rosuvastatin | Phase 3 | Small molecule | PCSK9 (laroprovstat component) + HMG-CoA reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Lepodisiran | Phase 3 | RNA / oligonucleotide | LPA gene / apolipoprotein(a) mRNA | Partial signal | NCT05565742: Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180 (Baseline, Days 60 - 180): 16 mg LY3819469 -39.0% ± 7.37 vs 96 mg LY3819469 -74.4% ± 2.16 vs 400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) -93.7% ± 0.38 vs Placebo 3.1% ± 8.99; p=<0.001 (16 mg LY3819469 vs Placebo), p=<0.001 (96 mg LY3819469 vs Placebo), p=<0.001 (400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) vs Placebo) | |
| Lerodalcibep (Lerochol) | Phase 3 | Protein / enzyme therapeutic | PCSK9 | Reliable signal | NCT04797104: LDL-C at Week 24: placebo-adjusted reduction of 58.61% (P<.0001); co-primary endpoint, mean of Weeks 22 and 24: placebo-adjusted reduction of 65.0% (P<.0001) NCT05004675: LDL-C change from baseline at Day 270 (mITT): -53% with lerodalcibep vs -45.3% with inclisiran (P=0.0319); per-protocol: -55.4% vs -45.4% (P=0.005) | |
| Maridebart Cafraglutide (MariTide) | Phase 3 | Peptide | GLP-1R agonist; GIPR antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Muvalaplin | Phase 3 | Small molecule | Apolipoprotein(a) [apo(a)] kringle domain / apo(a)-apoB100 interaction | Partial signal | NCT05563246: Percent Change From Baseline in Lp(a) - Assessed Via Intact Lp(a) Assay (Baseline, Week 12): 10 mg LY3473329 -47.35% ± 4.811 vs 60 mg LY3473329 -81.57% ± 1.230 vs 240 mg LY3473329 -85.71% ± 0.927 vs Placebo 0.48% ± 6.382; p=<.001 (10 mg LY3473329 vs Placebo), p=<.001 (60 mg LY3473329 vs Placebo), p=<.001 (240 mg LY3473329 vs Placebo) | |
| NL003 | Phase 3 | Gene therapy / editing | Hepatocyte growth factor (HGF) | not yet graded | No reviewed efficacy summary in this indication | |
| Obicetrapib | Phase 3 | Small molecule | CETP | Partial signal | NCT05142722: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10mg -29.94% (Standard Error 1.104) vs Placebo 2.7% (Standard Error 1.571) NCT05425745: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10 mg -36.05% (Standard Error 1.769) vs Placebo 0.25% (Standard Error 2.48) | |
| Obicetrapib / Ezetimibe (Evlarco) | Phase 3 | Small molecule | CETP, NPC1L1 | Partial signal | NCT06005597: Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days): Fixed Dose Combination -45.58% (Standard Error 3.465) vs Placebo 3.03% (Standard Error 3.564) | |
| Olpasiran | Phase 3 | RNA / oligonucleotide | LPA gene / apolipoprotein(a) mRNA | Partial signal | NCT04270760: Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36 (Baseline and Week 36): Group 1: Olpasiran 10 mg Q12W -66.91% ± 1.78 vs Group 2: Olpasiran 75 mg Q12W -93.78% ± 1.78 vs Group 3: Olpasiran 225 mg Q12W -97.53% ± 1.82 vs Group 4: Olpasiran 225 mg Q24W -96.89% ± 1.85 vs Group 5: Placebo Q12W 3.60% ± 1.89; p=<0.001 (Group 1: Olpasiran 10 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 2: Olpasiran 75 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 3: Olpasiran 225 mg Q12W vs Group 5: Placebo Q12W), p=< 0.001 (Group 4: Olpasiran 225 mg Q24W vs Group 5: Placebo Q12W) | |
| Ongericimab (Junshida) | Phase 3 | Monoclonal antibody | PCSK9 | Reliable signal | NCT05325203: Percent change in LDL-C from baseline to week 24 (JS002-005/NCT05325203, HeFH, 135 patients): ongericimab 150mg Q2W -69.4% vs placebo (p<0.0001); ongericimab 450mg Q4W -80.6% vs placebo (p<0.0001) NCT04781114: LDL-C percentage change from baseline to week 24 vs placebo: 150 mg Q2W -67.7% (95% CI -72.5% to -63.0%; P<0.0001); 300 mg Q4W -61.2% (95% CI -67.1% to -55.2%; P<0.0001). | |
| Orforglipron (Foundayo) | Phase 3 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Pelacarsen | Phase 3 | RNA / oligonucleotide | Apolipoprotein(a) mRNA | Partial signal | NCT05305664: Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis Schedule (Up to Week 52): Pelacarsen (TQJ230) 0.16 Apheresis sessions received per week (IQR 0.04 to 0.25) vs Placebo 0.93 Apheresis sessions received per week (IQR 0.9 to 1) | |
| Pemafibrate (Parmodia) | Phase 3 | Small molecule | PPAR-alpha | Partial signal | No reviewed efficacy summary in this indication | |
| PMR (cilostazol ER) | Phase 3 | Small molecule | Phosphodiesterase 3 (PDE3) | Weak signal | No reviewed efficacy summary in this indication | |
| Pravafenix | Phase 3 | Small molecule | HMG-CoA reductase / PPAR-alpha | Partial signal | No reviewed efficacy summary in this indication | |
| QLC7401 | Phase 3 | RNA / oligonucleotide | PCSK9 | not yet graded | No reviewed efficacy summary in this indication | |
| Ranolazine | Phase 3 | Small molecule | Cardiac late sodium current (late INa, Nav1.5) | Partial signal | NCT00099788: The primary end point occurred in 696 patients (21.8%) in the ranolazine group and 753 patients (23.5%) in the placebo group (hazard ratio 0.92). missed NCT01562041: Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Index (Baseline up to Day 15): Ranolazine 500 mg — Test 1: 3.211 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.6553); Test 2: 2.822 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0289); Test 3: 3.228 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.891); Test 4: 2.502 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.8884); Change From Baseline in Maximum ST/Heart Rate Index: -0.605 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0482) | |
| Recaticimab | Phase 3 | Monoclonal antibody | PCSK9 | Reliable signal | NCT04844125: Change in LDL-C from baseline at Week 12: -54.4% recaticimab vs -4.5% placebo; treatment difference -49.8 percentage points (95% CI -55.8 to -43.9), P<0.0001 NCT04849000: LDL-C reduction vs placebo at the primary endpoint timepoint: 150 mg Q4W -49.6% (95% CI 44.2-54.9%); 300 mg Q8W -52.8% (95% CI 48.3-57.2%); 450 mg Q12W -45.0% (95% CI 41.0-49.0%); P<0.0001 for all comparisons. | |
| Retatrutide | Phase 3 | Peptide | GLP-1/GIP/glucagon receptor (triple) | not yet graded | No reviewed efficacy summary in this indication | |
| Ribupatide | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| SAL003 | Phase 3 | Monoclonal antibody | PCSK9 | Partial signal | No reviewed efficacy summary in this indication | |
| Sarpogrelate (Anplag) | Phase 3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Sumecigrel | Phase 3 | Small molecule | P2Y12 platelet receptor | Partial signal | NCT03599284: Primary, inhibition of ADP-induced platelet aggregation (%IPA) at day 28: vicagrel 20/5 mg 30.19%, 24/6 mg 35.02%, 30/7.5 mg 45.61%, clopidogrel 32.55%; the paper reports these as comparable across all groups (P=0.0694) and sets no non-inferiority margin. | |
| SYH2053 | Phase 3 | RNA / oligonucleotide | PCSK9 | Partial signal | No reviewed efficacy summary in this indication | |
| Tafolecimab (Sintbilo) | Phase 3 | Monoclonal antibody | PCSK9 | Reliable signal | NCT04289285: LDL-C percent change from baseline to week 48, treatment difference vs placebo: -65.0% (97.5% CI: -70.2%, -59.9%) for tafolecimab 450 mg Q4W; -57.3% (97.5% CI: -64.0%, -50.7%) for 600 mg Q6W; both P < 0.0001 NCT04709536: Percent change in LDL-C from baseline to Week 12: tafolecimab -68.9% (SE 1.4%) vs placebo -5.8% (SE 1.8%); treatment difference -63.0% (95% CI -66.5% to -59.6%, P<0.0001) | |
| Ziltivekimab | Phase 3 | Monoclonal antibody | Interleukin-6 | Partial signal | NCT05021835: 3-point MACE (CV death, non-fatal MI, non-fatal stroke): HR 0.99 (95% CI 0.88-1.11) for ziltivekimab vs placebo. missed | |
| Neovasculgen | Phase 2/3 | Gene therapy / editing | VEGF165 gene therapy (angiogenic plasmid) | Partial signal | NCT03068585: Pain-free walking distance increased in the pCMV-vegf165 (Neovasculgen) treatment group by 110.4% at 6 months, versus no positive results in the standard-treatment control group | |
| ABP-745 | Phase 2 | Small molecule | NLRP3 inflammasome | not yet graded | No reviewed efficacy summary in this indication | |
| ACP-01 | Phase 2 | Biologic (subtype unspecified) | Autologous angiogenic cell precursor (ACP) therapy | Partial signal | NCT02551679: Primary composite (de-novo gangrene, doubling of wound size, major amputation or death within 1 year): 12 of 46 participants on ACP-01 vs 3 of 21 on placebo, hazard ratio 2.046 (95% CI 0.577 to 7.255), p=0.258 (CT.gov posted results). missed | |
| APAC | Phase 2 | Peptide | Vascular injury site glycocalyx / coagulation cascade | not yet graded | No reviewed efficacy summary in this indication | |
| Berberine Ursodeoxycholate (HTD1801) | Phase 1/2 | Small molecule | AMPK pathway / NLRP3 inflammasome (dual) | Weak signal | NCT03381287: Day 28, 2000 mg/day (highest dose) vs placebo: total cholesterol -8.2% (P=0.0004); LDL-C -10.4% (P=0.0006). Lower doses (500 mg, 1000 mg) did not reach significance. | |
| ALN-ANG3 | Phase 1 | RNA / oligonucleotide | ANGPTL3 | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 63 furthest-along competitors are listed; 60 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Compare side by side
4 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(89 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Farxiga / Forxiga (Dapagliflozin) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (11)
November 2026 (2)
December 2026 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (39)
January 2027 (2)
February 2027 (3)
April 2027 (4)
What to watch
What to watch
What to watch
What to watch
May 2027 (3)
What to watch
What to watch
What to watch
June 2027 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
July 2027 (4)
What to watch
What to watch
What to watch
What to watch
August 2027 (1)
What to watch
September 2027 (1)
What to watch
October 2027 (4)
What to watch
What to watch
What to watch
What to watch
November 2027 (3)
What to watch
What to watch
What to watch
December 2027 (8)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2028 (20)
January 2028 (1)
What to watch
February 2028 (2)
June 2028 (3)
What to watch
What to watch
What to watch
July 2028 (3)
August 2028 (3)
What to watch
What to watch
What to watch
September 2028 (2)
October 2028 (1)
What to watch
November 2028 (2)
December 2028 (3)
What to watch
What to watch
What to watch
2029 (14)
January 2029 (3)
What to watch
What to watch
What to watch
March 2029 (1)
What to watch
April 2029 (1)
What to watch
July 2029 (2)
August 2029 (4)
What to watch
What to watch
What to watch
What to watch
September 2029 (1)
What to watch
2030 (4)
May 2030 (1)
What to watch
July 2030 (1)
What to watch
October 2030 (1)
What to watch
December 2030 (1)
What to watch
2031 (1)
March 2031 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent